Qapzola receives setback from FDA committee

American Pharmacy News Reports | Dec 31, 2016

The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate in | File photo

The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
Qapzola’s recommendation from the committee is not bound to the FDA. The FDA does, however, make the final decision when it comes to an approval for the drug.
The medication’s Prescription Drug User Fee Act date was Dec. 11.